ATLANTA, May 13, 2011 /PRNewswire/ -- To mark HIV Vaccine Awareness Day on May 18, Dr. Harriet L. Robinson, CSO of GeoVax Labs, Inc. (OTCBB: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, has written an article for The Scientist outlining recent progress toward the development of an effective HIV vaccine.
The article, titled "Progress toward an HIV/AIDS vaccine: Recent successes and ongoing efforts to develop a successful vaccine," was published on The Scientist's website on May 11. Dr. Robinson first reviews a collaborative effort based in Thailand that culminated in 2009 with the first encouraging results from an HIV vaccine efficacy trial. She then summarizes ongoing work at GeoVax involving a combination DNA-vaccinia virus vaccine. The article concludes with a brief look at several other companies' efforts toward a vaccine.
"As we reflect on the past progress that has been made to develop an HIV/AIDS vaccine and look to the future advancements of these efforts, we have cause for optimism," writes Dr. Robinson in the article. "Tremendous progress has been, and is continuing to be made."
To read the article in its entirety, please visit:
About GeoVax Labs
GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV (Human Immunodeficiency Virus – that leads to AIDS) and other infectious agents. Our goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward. GeoVax's vaccines are unique in expressing virus like particles that display the trimeric membran
|SOURCE GeoVax Labs, Inc.|
Copyright©2010 PR Newswire.
All rights reserved